SCHEMBL13612207

SCHEMBL13612207

CNc1cccc(OCCNC(=O)[C@H](O)CCO)c1C(=N)Nc1ccc(OCc2cscn2)c(Cl)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 5/20 0.39
ERBB2 P04626 6/20 0.33
KCNH2 Q12809 3/20 0.33
MET P08581 1/20 0.33
GPR142 Q7Z601 1/20 0.33
GRM4 Q14833 1/20 0.33
KDR P35968 5/20 0.32
FLT1 P17948 1/20 0.32
EPHA2 P29317 1/20 0.32
EPHB4 P54760 1/20 0.32
ACP1 P24666 1/20 0.32
PTPN12 Q05209 1/20 0.32
PTPN13 Q12923 1/20 0.32
SSU72 Q9NP77 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
PPARD Q03181 1/20 0.31
ALDH1A1 P00352 1/20 0.31
LCK P06239 1/20 0.31
POLB P06746 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13612211 1.00 EGFR (0.39) EGFRERBB2KCNH2METGPR142
SCHEMBL13612256 0.89 EGFR (0.37) EGFRERBB2KCNH2METGPR142
SCHEMBL13612041 0.89 EGFR (0.37) EGFRERBB2KCNH2METGPR142
SCHEMBL4483812 0.79 EGFR (0.58) EGFRERBB2KCNH2
SCHEMBL4479825 0.79 EGFR (0.58) EGFRERBB2KCNH2
SCHEMBL13612030 0.69 EGFR (0.52) EGFRERBB2KCNH2LCK
SCHEMBL13612242 0.69 ERBB2 (0.52) EGFRERBB2KCNH2GRM4LCK
SCHEMBL13612635 0.69 ERBB2 (0.50) EGFRERBB2KCNH2LCK
SCHEMBL13611880 0.69 ERBB2 (0.46) EGFRERBB2KCNH2LCK
SCHEMBL4480630 0.68 EGFR (0.56) EGFRERBB2KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7625908-B2 Quinazoline derivatives ASTRAZENECA AB (SE) 2009-12-01 US disclosed
US-20070244136-A1 Quinazoline Derivatives ASTRAZENECA AB (SE) 2007-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070244136-A1 Quinazoline Derivatives ERBB2, ABL1, MKI67 EGFR 10/4885ERBB2 1/4885KCNH2 3674/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.